DOCSLIB.ORG

The Influence of Drop Size on Pupil Dilatation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Influence of Drop Size on Pupil Dilatation Eye (1991) 5, 615-619 The Influence of Drop Size on Pupil Dilatation R. H. GRAY Oxford Summary The clinical efficacy of reduced size dilating drops (micro drops), was assessed in 60 patients. For each patient, one eye received the standard 'minim' drop size (26 microlitres) while the fellow eye received a micro drop of five microlitres. In 20 patients tropicamide 1 % was followed after two minutes by phenylephrine 10%, another 20 patients were given tropicamide 1 % alone, and for the last 20 patients, 0.5% tropic amide was used. Satisfactory mydriasis was achieved for all pupils except those receiving micro drops of tropicamide 0.5% (25 micrograms tropicamide). Tropicamide 1 % in micro drop formulation (50 micrograms tropicamide) gave almost identical mydriasis to that from standard drops (containing 250 micrograms tropicamide). Tropicamide 1 % in combination with phenylephrine 10% was superior to tropicamide 1 % alone, after standard or micro drop administration. The micro drops used in this study were effective, easy to administer, and caused less patient discomfort. Systemic effects of topically applied medi­ The average 'minim' drop volume of Phe­ cations have become well recognised nylephrine 10'/"0, Tropicamide 1 %, and Trop­ phenomena. i-b Adverse reactions may be icamide 0.5% was measured and found to be minimised by occluding the lid punctae, 26 microlitres. When the same drugs were reducing the concentration of administered administered via a 30 gauge Rycroft cannula, drug, or reducing the drop volume. It is the the average volume was 5 microlitres. (See latter manoeuvre that was investigated in this Figure 1) study, using the degree of pupil dilatation as For all patients studied, vertical pupil diam­ the measure of clinical efficacy of the drugs eter was measured using the focussed slit examined. beam on a series 900 Haag-Streit slit lamp, immediately before instillation of drops, and Materials and Methods at 20 minutes. For all eyes, a single drop of the Sixty patients requiring diagnostic pupil dila­ drug studied was instilled into the lower con­ tation were selected and tested in the setting junctival fornix. of outpatient clinics between June and For the first20 patients (group 1), both 10% December 1989. Those already on eye drops phenylephrine and tropicamide 1% were were excluded, as were those with obvious used. One eye was chosen at random to anterior segment pathology or history of receive these drugs in micro-drop formula­ intraocular surgery. Patients with diabetes tion, while the other eye received the stan­ mellitus or chronic glaucoma were also dard drop size; two minutes elapsed before excluded because of the autonomic dysfunc­ the second drop was given. tion that may affect the pupil in these For the next 20 patients (group 2), 1% conditions.7,8 Tropicamide was used alone, again with the Correspondence to: Mr R. H. Gray, Oxford Eye Hospital, Walton St, Oxford. 616 R. H. GRAY Fig. 1 A 30 gauge Rycroft cannula. secured to minim dropper. was used to administer the micro drops. standard drop in one eye.and micro-drop in when the micro-drop formulation was used in the other. fellow eyes. (See Table I) For the final 20 patients (group 3).0.5% In group 2 (1 % tropicamide alone).aver­ Tropicamide was used alone in the same way. age pupil diameter rose by 3.87 mm when standard drops were used.and by 3.7 mm for Results those pupils dilated with the micro-drop for­ In Group 1 (tropicamide 1 'Yo and phenyl­ mulation in fellow eyes. ephrine 10% ), pupil diameter increased by an In group 3 (0.5% tropicamide alone). pupil average of 4.62 millimetres (mm) for the stan­ diameter rose by an average of 3.7 mm at 20 dard drop size at 20 minutes, and by 4.28 mm minutes for the standard drop size, and by 3.14 mm for the micro-drop formulation in fellow eyes. With a light stimulus provided by indirect ophthalmoscopy, it was noted that some pupil constriction occurred in eyes that had been dilated with a micro drop of O.5'Xl tropica­ mide. In all other eyes the pupils did not con­ strict 20 minutes after administration. It was 15 also noted that patients experienced much less ocular discomfort with the reduced drop size. A two way repeated measure Analysis of Group 1 Croup 2 Group 3 (9I.N:K- NORMAL DROP. 'II:IIT!:- MICRO DROP) Variance (ANOVA) was carried out on the data. (For the purposes of this analysis it was Fig. 2 Effect of drop size on pupil dilatation. Filled assumed that the two eyes of any patient bars represent large drops. striped bars represent behave so similarly that they can be regarded small drops. 1 = Tropicamide I% and phenylephrine 10%. 2 = Tropicamide 1% alone. 3 = (l.S'!,,, as a single eye tested on two occasions0). The Tropicamide alone. (I = standard error of the mean). results of the analyses, (see Table II) show THE INFLUENCE OF DROP SIZE ON PUPIL DlLATArION 617 Table I Mean pupil diameter (mm) at 0 and 20 min Illes Standard drop Micro drop Tropicamide 1 % + Phenylephrine 10%, 2.53-7.15. (4.62) 2.49-0.77. (4.28) Tropicamidc I 'X, 2.23-6.10. CU7) 2.22-5.92. (3.70) Tropicamide 0.5% 2.52-0.22. (3.70) 2.50-5.04. (3.14) (Change in pupil diameter in parentheses) that there were main effects of choice of drug demonstrated by Chrai et af. Ie on rabbit eyes (s), (f = 11.12, df = 2,57, p<U.OOOl) and using pilocarpine. He showed quite clearly drop size. (f = 3.50, df = 1, p<O.OOOJ). Also, that for a given amount of drug, maximum a significant interaction was found between efficacy was obtained when drop size was choice of drug(s) and drop size. (f 0;= 3.90, decreased from 30 to 5 microlitres. df = 2,57, p«U)2) This latter interaction was Human lacrimal fluid volume is about 7 analysed further by testing the significanceof microlitres, and the maximum quantity of the difference between the six means using fluidthat can be accommodated without spill­ III 13 Newman-Keuls a posteriori tests. These age is probably no more than 30 microlitres. tests confirmed that the combination of trop­ Blinking considerably increases the rate at icamide 1 'X, and phenylephrine 10% gave sig­ which this fluid is drained through the naso­ nificantly better dilatation than Tropicamide lacrimal apparatus. In this study the patients were allowed to blink, squeeze and wipe their 1 'X, alone. (p<O.Ol) this being true for the eyes as ·they desired, because it was felt that macro or micro drop regimen. Also confirmed this approach would more closely simulate the was the equal efficacy afforded by Tropica­ unsupervised administration of eye drops. mide 0.5°/r, when compared with Tropicamide One unexpected benefit to the patient of 1%, although in this case it was only true reduced drop size was greater comfort, to the when 'the macro drop of 0.5% tropicamide extent that patients often questioned whether was used (p<ll.OI). the drops had indeed gone into both eyes. The lack of squeezing, blinking, and wiping of the Discussion eyes probably aided the action of the micro It is well known that topically applied drugs drops. gain access to the nasolacrimal drainage One micro drop of tropicamide 0.5% gave system, decreasing topical efficacy and inadequate pupil dilatation, indicating that increasing the potential for systemic absorp­ the quantity of drug it contains (25 micro­ tion. It is also clear that loss of drug from the grams), falls below that required to achieve eye will increase as drop size increases. Yet satisfactory mydriasis. Moreover, the absence high concentrations of instilled drug in the of any significant differencein clinical efficacy pre-corneal tear film are required to achieve between a micro drop of 1 % Tropicamide satisfactory ocular penetration: not only is the (containing 50 micrograms) and a macro drop drug immediately diluted on contact with lac­ of 0.5% Tropicamide (containing 125 micro­ rimal fluid, but also the lacrimal fluid is itself grams), indicates that no more than 50 micro­ being turned over at a rate estimated to be grams of drug need be delivered to the eye to 16% per minute in humans. II The importance achieve maximum effect, provided it is of high drug concentration was elegantly delivered in a micro drop formulation. Table 2 Analysis of I'ariance. (ANOVA) Source Slim ofSQ DF Mean SQ Fratio Tail prob Condition (C) 22.3 2 11.12 7. 77 0.00 Error (8G) 1'11. 59 57 1.43 Dropsizc (D) 3.50 I 3. 50 21.05 O.DO DC 1. 26 2 0.03 3.90 0.02 Error (WG) 9.22 57 0.10 618 R. H. GRAY A statistically significant difference was ophthalmic drug delivery system capable of demonstrated for the pupil dilatation low dose administration is currently being achieved with a combination of 1 % tropica­ developed to circumvent this problem, and mide and 10% phenylephrine when the macro initial trial results have been promising. 17 drop was compared with the micro drop. However, the level of significancewas only at the 0.05 level. This difference in effect is sur­ r am most grateful to Dr Barney Reeves for his help prising, since Chrai et al.14 have shown in an with the statistical analysis of the data. animal model that the deleterious effect on the precorneal tear film concentration of a Keywords: Dilate; Dilatation; Drop Size; Mydria­ tropically applied drug caused by subsequent sis; Pupil.
Load more

Recommended publications
  • Chlorpromazine-Induced Cataract and Corneal Pigmentation
    Case Report Chlorpromazine-induced cataract and corneal pigmentation Chlorpromazine (CPZ) is a low-potency neuroleptic used bution was symmetrical in both eyes. Two independent clini- in the treatment of various psychiatric disorders.1 Chlorpro- cians documented the condition. The pupils were dilated with mazine-induced cataract and corneal pigmentation was first 1% tropicamide for retinoscopy. A dilatation of only 4 mm could described by Greiner & Berry in 1964.2 The prevalence in pa- be achieved. Fundus examination by indirect ophthalmoscopy tients treated over time with large doses of CPZ therapy, ranges was normal. Systemic examination was normal; apart from a from 15% to 74%. Though other low-potency neuroleptics like few extrapyramidal symptoms there were no other side-ef- thioridazine and fluphenazine have been reported to cause fects of CPZ, including skin discoloration. Investigations in- pigmentary changes, characteristic corneal and lenticular pig- cluding liver function tests and peripheral smear were nor- mentation is predominantly if not exclusively a side-effect of mal. With subjective correction, the patient’s vision improved CPZ. We report a case of a 45-year-old female with ocular to 6/9. With the psychiatrist’s consultation, CPZ was substi- effects due to long-term CPZ therapy for bipolar disease. tuted with trifluoperazine. Case report Discussion A 45-year-old female had been taking treatment for manic- Chlorpromazine is an aliphatic phenothiazine used in all depressive psychosis with chlorpromazine 300 mg per day for types of psychosis, especially schizophrenia. The adverse ef- 25 years. In addition, she was found to have received lithium fects include drowsiness, lethargy, postural hypotension, an- 300 mg and haloperidol 5 mg, both twice daily for florid psy- ticholinergic side-effects, infertility and extrapyramidal symp- chotic symptoms.
    [Show full text]
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972
    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • Acepromazine and Chlorpromazine As Pharmaceutical-Grade Alternatives to Chlorprothixene for Pupillary Light Reflex Imaging in Mice
    Journal of the American Association for Laboratory Animal Science Vol 59, No 2 Copyright 2020 March 2020 by the American Association for Laboratory Animal Science Pages 197–203 Acepromazine and Chlorpromazine as Pharmaceutical-grade Alternatives to Chlorprothixene for Pupillary Light Reflex Imaging in Mice Samantha S Eckley,1 Jason S Villano,1 Nora S Kuo,1 and Kwoon Y Wong2,* Studies of visual responses in isoflurane-anesthetized mice often use the sedative chlorprothixene to decrease the amount of isoflurane used because excessive isoflurane could adversely affect light-evoked responses. However, data are not available to justify the use of this nonpharmaceutical-grade chemical. The current study tested whether pharmaceutical-grade sedatives would be appropriate alternatives for imaging pupillary light reflexes. Male 15-wk-old mice were injected intraperitoneally with 1 mg/kg chlorprothixene, 5 mg/kg acepromazine, 10 mg/kg chlorpromazine, or saline. After anesthetic induction, anes- thesia maintenance used 0.5% and 1% isoflurane for sedative- and saline-injected mice, respectively. A photostimulus (16.0 log photons cm−2 s−1; 470 nm) was presented to the right eye for 20 min, during which the left eye was imaged for consensual pupillary constriction and involuntary pupil drift. Time to immobilization, loss of righting reflex, physiologic parameters, gain of righting reflex, and degree of recovery were assessed also. The sedative groups were statistically indistinguishable for all measures. By contrast, pupillary drift occurred far more often in saline-treated mice than in the sedative groups. Fur- thermore, saline-treated mice took longer to reach maximal pupil constriction than all sedative groups and had lower heart rates compared with chlorpromazine- and chlorprothixene-sedated mice.
    [Show full text]
  • Tropicamide Tropicamide Eye Drops
    Minims® Tropicamide Tropicamide Eye Drops Consumer Medicine Information Tell your doctor if you have or What is in this leaflet Before you use Minims have had any of the following Tropicamide This leaflet answers some common medical conditions: questions about Minims * glaucoma (high pressure in the Tropicamide, including how to use When you must not use it eye) the eye drops. * fast heartbeat or any heart Do not use Minims Tropicamide if It does not contain all the available condition or had heart surgery. you have an allergy to: information. It does not take the Tell your doctor if you are place of talking to your doctor or * any medicine containing pregnant or are breast-feeding. pharmacist. tropicamide Your doctor will discuss with you * any of the ingredients listed at the All medicines have benefits and the risks and benefits involved. risks. Your doctor has weighed the end of this leaflet. Tell your doctor if you wear risks of you using Minims Some of the symptoms of an allergic contact lenses. Tropicamide against the benefits they reaction may include: You should not wear contact lenses expect it will have for you. * shortness of breath while using this medicine. If you have any concerns about * wheezing or difficulty breathing using this medicine, ask your * swelling of the face, lips, tongue If you have not told your doctor doctor or pharmacist. about any of the above, tell or other parts of the body him/her before you start using Keep this leaflet with the medicine. * rash, itching or hives on the skin.
    [Show full text]
  • 208151Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208151Orig1s000 SUMMARY REVIEW NDA 208151, ISOPTO Atropine (atropine sulfate ophthalmic solution) 1% Cycloplegia, Mydriasis, Penalization of the healthy eye in the treatment of amblyopia Division Director Summary Review Material Reviewed/Consulted OND Action Package, including: Names of discipline reviewers Medical Officer Review Wiley Chambers, William Boyd 9/13/2016 CDTL Review William Boyd, Wiley Chambers 11/29/2016 Statistical Review Abel Eshete, Yan Wang 11/8/2016 Pharmacology Toxicology Review Aaron Ruhland, Lori Kotch 11/7/2016 CMC Review Haripada Sanker, Milton Sloan, Maotang Zhou, Denise Miller, Vidya Pai, Om Anand, Erin Andrews, Chunchun Zhang, Paul Perdue 10/12/2016, 11/10/2016 Clinical Pharmacology Review Abhay Joshi, Philip Colangelo 11/9/2016 OPDP/DPDP Carrie Newcomer 11/7/2016 OSI/DGCPC N/A Proprietary Name Michelle Rutledge, Yelena Maslov, Lubna Merchant 6/1/2016 Conditionally acceptable letter Todd Bridges 6/2/2016 OSE/DMEPA Michelle Rutledge, Yelena Maslov 6/8/2016 OSE/DDRE N/A OSE/DRISK N/A Project Manager Michael Puglisi OND=Office of New Drugs CDTL=Cross-Discipline Team Leader OSI/DGCPC=Office of Scientific Investigations/Division of Good Clinical Practice Compliance OPDP/DPDP=Office of Prescription Drug Promotion/Division of Prescription Drug Promotion OSE= Office of Surveillance and Epidemiology DMEPA=Division of Medication Error Prevention and Analysis DDRE= Division of Drug Risk Evaluation DRISK=Division of Risk Management Page 2 of 24 Reference ID: 4021108 NDA 208151, ISOPTO Atropine (atropine sulfate ophthalmic solution) 1% Cycloplegia, Mydriasis, Penalization of the healthy eye in the treatment of amblyopia Division Director Summary Review Signatory Authority Review Template 1.
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Tropicamide 2018 Newborn Use Only
    Tropicamide 2018 Newborn Use Only Alert Watch for apnoeas and abdominal distension following administration. Lower concentration solutions and regimens minimising number of additional drops are recommended. Indication Induction of mydriasis and cycloplegia for diagnostic and therapeutic ophthalmic procedures. Action Anticholinergic drug that produces pupillary dilatation by inhibiting the sphincter pupillae muscle and paralysis of accommodation. Drug Type Antimuscarinic. Trade Name Minims Tropicamide Eye Drops Mydriacyl Eye drops Presentation Minims Tropicamide Eye Drops 0.5%, 1.0% solution. Mydriacyl Eye drops 0.5%, 1.0% 15 mL (multidose—excipients benzalkonium chloride 0.01%, sodium chloride, disodium edetate, hydrochloric acid and/or sodium hydroxide, purified water). Dosage/Interval Use in combination with phenylephrine 2.5% with or without cyclopentolate 0.5%. REGIMEN 1: Phenylephrine 2.5% + cyclopentolate 0.5% + tropicamide 0.5% eye drops [1-4]. Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation. REGIMEN 2: Phenylephrine 2.5% + tropicamide 0.5% eye drops [5-7]. Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation. Dark irides may require additional drops. Maximum daily dose REGIMEN 1: 3 drops of each agent. REGIMEN 2: 4 drops of each agent. Route Topical instillation into the eyes from the container or use a microdrop (5–7 microL) cannula. Preparation/Dilution Administration Apply pressure to the lacrimal sac during and for 60 seconds after instillation of eye drop to minimise systemic absorption.
    [Show full text]
  • Asis with Tropicamide and Phenylephrine on Intraocular Pressure
    Adediji AK, et al., J Ophthalmic Clin Res 2019, 6: 049 DOI: 10.24966/OCR-8887/100049 HSOA Journal of Ophthalmology and Clinical Research Research Article line at all the follow up periods except at 45 minutes where it was Effects of Diagnostic Mydri- slightly higher (12.11±2.87mmHg). These differences in mean IOP change were statistically significant (p<0.05). At all the follow-up asis with Tropicamide and periods, 8.8%-14.6% of participant’s right eyes had large IOP ele- vations (>5mmHg but <10mmHg). Multiple linear regression anal- Phenylephrine on Intraocular ysis showed that pre dilatation IOPs were positively correlated to post dilatation IOPs. Pressure Conclusion: There is need to recheck IOP post dilatation prefera- Adediji AK, Adio AO and Fiebai B* bly at 45 minutes in all patients who have had diagnostic mydriasis to prevent damage to the optic nerve. Diagnostic mydriasis could Department of Ophthalmology, University of Port Harcourt Teaching Hospi- safely be done using small concentrations of tropicamide and phen- tal, Port Harcourt, Nigeria ylephrine. Keywords: Diagnostic mydriasis; Intraocular pressure; Mydriasis; Phenylephrine; Tropicamide Introduction Intraocular Pressure (IOP) is the tissue pressure within the eye which is determined by the balance between aqueous humor produc- tion and outflow, which under normal circumstances is nearly equal. The normal distribution of IOP within the general population is 11- 21mmHg [1]. Intraocular pressure can be affected by a range of fac- tors like time of the day, heartbeat, respiration, exercise, fluid intake, Abstract posture, blinking, eye movements, valsalva manoeuvres and med- ications; including those used for pupillary dilatation [2-4].
    [Show full text]
  • Maintenance Drug List Below Is Not Comprehensive and Is Subject to Change Without Prior Notification
    Maintenance Drugs Maintenance drugs are used on a continuing basis for the treatment of chronic conditions. Select health plans require that pharmacy benefit maintenance drugs are filled at Kaiser Permanente Washington Mail Order or Kaiser Permanente Clinic Pharmacies for ongoing health plan coverage. Please consult your Evidence of Coverage or call Member Services at 1-888-901-4636 if you have questions about your drug coverage. Non-maintenance drugs are generally used for episodic treatment, are considered narrow therapeutic index by Kaiser Permanente Washington, or are schedule 2 controlled substances. Non-maintenance products include: opioids, opioid reversal agents, opioid dependence agents, benzodiazepines, skeletal muscle relaxants, schedule 2 stimulants, vaccines, oral antibiotics, antiemetics, cough/cold/allergy products, emergency contraception, epinephrine pens, bowel preparations, smoking cessation, prednisone, enoxaparin, cyclosporine, digoxin, dofetilide, everolimus, lithium, mycophenolate, sirolimus, sotalol, tacrolimus, theophylline, and warfarin. The maintenance drug list below is not comprehensive and is subject to change without prior notification. Coverage is provided by Kaiser Permanente Health Plan of Washington and Kaiser Permanente Health Plan of Washington Options, Inc. MAINTENANCE DRUG LIST: ADHD/ANTI-NARCOLEPSY AGENTS DICLOFENAC NALFON ARMODAFINIL DICLOFENAC POTASSIUM NAPRELAN ATOMOXETINE DICLOFENAC SODIUM DR NAPROSYN CLONIDINE HCL ER DICLOFENAC SODIUM ER NAPROXEN GUANFACINE ER DICLOFENAC SODIUM/MISOPROSTOL NAPROXEN
    [Show full text]
  • Appendix 1 BNF Codes of Drugs Lists Used to Define Exposure Groups
    Appendix 1 BNF Codes of drugs lists used to define exposure groups. Anticholinergic antipsychotics d411. Chlorpromazine d412. Chlorpromazine d413. Chlorpromazine d414. Chlorpromazine d415. Chlorpromazine d41a. Chlorpromazine d41b. Chlorpromazine d41c. Chlorpromazine d41d. Chlorpromazine d4b1. Perphenazine d4e1. PROMAZINE d4ex. PROMAZINE d4g.. Thioridazine d4g1. Thioridazine d4g2. Thioridazine d4g3. Thioridazine d4g5. Thioridazine d4g7. Thioridazine d4gp. Thioridazine d4gt. Thioridazine d4gu. Thioridazine d4gv. Thioridazine d4gw. Thioridazine d4gz. Thioridazine d4h.. Trifluoperazine d4h1. Trifluoperazine d4h2. Trifluoperazine d4h3. Trifluoperazine d4h4. Trifluoperazine d4hs. Trifluoperazine d4ht. Trifluoperazine d4hu. Trifluoperazine d4hx. Trifluoperazine d4l2. CLOZAPINE d4r1. OLANZAPINE d4r3. OLANZAPINE d4r7. OLANZAPINE d4s1. QUETIAPINE d4s2. QUETIAPINE d4s3. QUETIAPINE d4s5. QUETIAPINE d4ss. QUETIAPINE d4sx. QUETIAPINE Tricyclic antidepressants d7... d71.. Amitriptyline d711. Amitriptyline d712. Amitriptyline d713. Amitriptyline d719. Amitriptyline d71a. Amitriptyline d71b. Amitriptyline d71c. Amitriptyline d71d. Amitriptyline d71e. Amitriptyline d71f. Amitriptyline d71u. Amitriptyline d71v. Amitriptyline d71w. Amitriptyline d71y. Amitriptyline d71z. Amitriptyline d73.. Clomipramine d731. Clomipramine d732. Clomipramine d733. Clomipramine d736. Clomipramine d73s. Clomipramine d73t. Clomipramine d73u. Clomipramine d73v. Clomipramine d73w. Clomipramine d73z. Clomipramine d75.. DOSULEPIN d751. DOSULEPIN d752. DOSULEPIN d755. DOSULEPIN d756.
    [Show full text]
  • Queensland Health List of Approved Medicines
    Queensland Health List of Approved Medicines Drug Form Strength Restriction abacavir * For use in accord with PBS Section 100 indications * oral liquid See above 20 mg/mL See above tablet See above 300 mg See above abacavir + lamivudine * For use in accord with PBS Section 100 indications * tablet See above 600 mg + 300 mg See above abacavir + lamivudine + * For use in accord with PBS Section 100 indications * zidovudine tablet See above 300 mg + 150 mg + 300 mg See above abatacept injection 250 mg * For use in accord with PBS Section 100 indications * abciximab (a) Interventional Cardiologists for complex angioplasty (b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * injection See above 10 mg/5 mL See above abiraterone For use by medical oncologists as per the PBS indications for outpatient and discharge use only tablet See above 250 mg See above 500 mg See above acamprosate Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. enteric tablet See above 333 mg See above acarbose For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents tablet See above 50 mg See above 100 mg See above acetazolamide injection 500 mg tablet 250 mg acetic acid ear drops 3% 15mL solution 2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL Generated on: 30-Aug-2021 Page 1 of 142 Drug Form Strength Restriction acetylcysteine injection For management of paracetamol overdose 2 g/10 mL See above 6 g/30 mL See above aciclovir cream Infectious disease physicians, haematologists and oncologists 5% See above eye ointment For use on the advice of Ophthalmologists only.
    [Show full text]